VEGF and Ki-67 Expression in Colorectal Cancer: The Long-Term Impact on Recurrence and Mortality

Imagem de Miniatura
Arquivos
art_SANTOS_VEGF_and_Ki67_Expression_in_Colorectal_Cancer_The_2022.PDF (1.28 MB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
KARE PUBL
Autores
SANTOS, Pedro Miguel Dias dos
PEREIRA, Ines Sa
MARTINS, Sandra F.
Citação
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, v.6, n.3, p.258-267, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives: Colorectal cancer is the most frequent and mortal cancer in Portugal. Both angiogenesis and cellular proliferation are core mechanisms to tumoral progression, with VEGF (Vascular Endothelial Growth Factor) and Ki-67, respectively, being widely known markers of those two processes. The purposes of this study are to comprehend VEGF and Ki-67's impact on colorectal cancer prognosis which include assessing its expression in primary colorectal cancer of patients who underwent surgery, establishing associations between the expression of VEGF and Ki-67 and discovering hypothetical associations between these biomarkers and clinicopathological aspects, relapse, and mortality of patients. Methods: A retrospective study was conducted in our hospital by including 512 patients submitted to surgery, from 2005 to 2010, with a post-operatory diagnosis of colorectal adenocarcinoma. The evaluation of expression of VEGF and Ki-67 in the obtained tissue was made through immunohistochemistry technique. The statistical analysis resourced to association tests and survival analysis. Results: VEGF-A showed association with the variable gender (p-value of 0.016), with its expression being more frequent in men. VEGF- C expression is more common in colon than in rectum (p- value of 0.042). VEGF-C is significantly associated with Ki-67 (p-value of 0.036), with 69.7% of cases where both are positive. All markers are significantly associated with the grade of differentiation, with the VEGF family generally more present in well or moderately differentiated tumours and Ki-67 in the poorly differentiated. While the survival time was generally lower in the presence of any marker or combination, no significant differences were found among the survival analysis. Conclusion: VEGF-A, VEGF- C and Ki-67 expression did not show impact on the prognosis of this sample of patients. There was no significant association with a poorer overall survival or a reduced disease-free survival.
Palavras-chave
Colorectal cancer, Ki-67, mortality, recurrence, VEGF
URI
https://observatorio.fm.usp.br/handle/OPI/51628
Referências
  1. Battaglin F, 2018, EXPERT REV ANTICANC, V18, P251, DOI 10.1080/14737140.2018.1428092
  2. Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
  3. Chan AT, 2010, GASTROENTEROLOGY, V138, P2029, DOI 10.1053/j.gastro.2010.01.057
  4. Chaudary N, 2011, GYNECOL ONCOL, V123, P393, DOI 10.1016/j.ygyno.2011.07.006
  5. Chen JX, 2012, ASIAN PAC J CANCER P, V13, P2229, DOI 10.7314/APJCP.2012.13.5.2229
  6. Chung JY, 2014, PROTEOME SCI, V12, DOI 10.1186/1477-5956-12-27
  7. Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
  8. Faratzis G, 2009, ORAL ONCOL, V45, P584, DOI 10.1016/j.oraloncology.2008.08.002
  9. Ferroni P, 2006, ONCOLOGY-BASEL, V71, P176, DOI 10.1159/000106072
  10. George ML, 2001, NEOPLASIA, V3, P420, DOI 10.1038/sj.neo.7900186
  11. Gheytanchi E, 2014, ASIAN PAC J CANCER P, V15, P3065, DOI 10.7314/APJCP.2014.15.7.3065
  12. Jansson A, 1997, APMIS, V105, P730, DOI 10.1111/j.1699-0463.1997.tb05078.x
  13. Khalil K, 2018, DUHOK MEDICAL J, V12, P45
  14. Khorana AA, 2003, CANCER, V97, P960, DOI 10.1002/cncr.11152
  15. Kim BH, 2020, J PATHOL TRANSL MED, V54, P1, DOI 10.4132/jptm.2019.09.28
  16. Lee GH, 2015, EJSO-EUR J SURG ONC, V41, P300, DOI 10.1016/j.ejso.2014.11.001
  17. Lee JC, 2000, EUR J CANCER, V36, P748, DOI 10.1016/S0959-8049(00)00003-4
  18. Li LT, 2015, MOL MED REP, V11, P1566, DOI 10.3892/mmr.2014.2914
  19. Li P, 2016, ONCOL RES TREAT, V39, P696, DOI 10.1159/000450623
  20. Liang JF, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-71
  21. Luo ZW, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5324-y
  22. Martins SF, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/131685
  23. Martins SF, 2013, CANCER GENOM PROTEOM, V10, P55
  24. Mayerhofer K, 2004, GYNECOL ONCOL, V92, P175, DOI 10.1016/j.ygyno.2003.10.028
  25. Melling N, 2016, J CLIN PATHOL, V69, P209, DOI 10.1136/jclinpath-2015-202985
  26. Mody K, 2018, CANCER J, V24, P165, DOI 10.1097/PPO.0000000000000328
  27. Mohamed SY, 2019, J GASTROINTEST CANC, V50, P23, DOI 10.1007/s12029-017-0014-y
  28. Mousa Luay, 2015, Biomark Cancer, V7, P13, DOI 10.4137/BIC.S25250
  29. Pareceres SPED, RASTR CANCR COL
  30. Park S, 2016, CANCER RES TREAT, V48, P518, DOI 10.4143/crt.2015.093
  31. Sagaert X, 2018, PATHOBIOLOGY, V85, P72, DOI 10.1159/000486721
  32. Salminen E, 2005, WORLD J GASTROENTERO, V11, P3245, DOI 10.3748/wjg.v11.i21.3245
  33. Simon K, 2016, CLIN INTERV AGING, V11, DOI 10.2147/CIA.S109285
  34. Sveen A, 2020, NAT REV CLIN ONCOL, V17, P11, DOI 10.1038/s41571-019-0241-1
  35. Tong GJ, 2020, ONCOL REP, V43, P1187, DOI 10.3892/or.2020.7511
  36. Treanor D, 2007, CLIN ONCOL-UK, V19, P769, DOI 10.1016/j.clon.2007.08.012
  37. van Triest B, 2000, CLIN CANCER RES, V6, P1063
  38. Yin L, 2020, ONCOL LETT, V19, P3558, DOI 10.3892/ol.2020.11450
  39. Zafirellis K, 2008, J SURG RES, V147, P99, DOI 10.1016/j.jss.2007.05.041
  40. Zheng S, 2003, WORLD J GASTROENTERO, V9, P1227, DOI 10.3748/wjg.v9.i6.1227

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - ODS/03